Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.

abstract：:Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever pos...

journal_title：Expert review of anticancer therapy

authors： Vijayamurugan N,Bakhshi S

更新日期：2014-02-01 00:00:00

abstract：:Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma...

journal_title：Expert review of anticancer therapy

authors： Tsao CK,Gartrell BA,Oh WK,Galsky MD

更新日期：2012-12-01 00:00:00

abstract：:Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered...

journal_title：Expert review of anticancer therapy

authors： Giaj-Levra N,Borghetti P,Bruni A,Ciammella P,Cuccia F,Fozza A,Franceschini D,Scotti V,Vagge S,Alongi F

更新日期：2020-05-01 00:00:00

abstract：:Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

journal_title：Expert review of anticancer therapy

authors： Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

更新日期：2016-01-01 00:00:00

abstract：:Ductal carcinoma in situ is a premalignant disease of the breast with a rapidly rising incidence. For women with localized ductal carcinoma in situ, randomized trials have shown that radiation therapy following conservative surgery lowers the relative risk of progression to invasive disease by 60%. Therefore, followin...

journal_title：Expert review of anticancer therapy

authors： Smith BD,Smith GL,Buchholz TA

更新日期：2008-03-01 00:00:00

abstract：:Tumors of the CNS frequently have devastating consequences in terms of cognitive and motor function, personality and mortality. Despite decades of work, current therapies have done little to alter the course of these deadly diseases. The discovery that chaperones/heat-shock proteins play an important role in tumor bio...

journal_title：Expert review of anticancer therapy

authors： Graner MW,Bigner DD

更新日期：2006-05-01 00:00:00

abstract：INTRODUCTION:Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure. Despite application of different modalities such as chemotherapy, radiotherapy and surgery, patient prognosis remains very poor and therapies are ineffective. Much research currently focuses on the application of novel approa...

journal_title：Expert review of anticancer therapy

authors： Bakker E,Guazzelli A,Ashtiani F,Demonacos C,Krstic-Demonacos M,Mutti L

更新日期：2017-09-01 00:00:00

abstract：:Childhood acute myeloid leukemia is rare, but accounts for a significant number of malignancy-related deaths in this age group. However, the prognosis has improved over past decades, and survival rates of 60% and above have been reported. Still, this implies that more than a third of children and adolescents die from ...

journal_title：Expert review of anticancer therapy

authors： ter Bals E,Kaspers GJ

更新日期：2005-10-01 00:00:00

abstract：:Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis. In addition, limited active therapeutic options are available. The cytotoxic drug gemcitabine and the inhibition of the mTOR pathway have demonstrated modest activity in sarcomas as monotherapy. However, prec...

journal_title：Expert review of anticancer therapy

authors： Martin-Liberal J,Tirado OM,García del Muro X

更新日期：2015-03-01 00:00:00

abstract：:A number of cancers occur with increased frequency in individuals with HIV infection. There is a debate as to whether or not hepatocellular cancer is one of these tumors. This article reviews the current data regarding incidence etiology, treatment and outcome for HIV-related hepatocellular cancer. It also attempts to...

journal_title：Expert review of anticancer therapy

authors： Powles T,Macdonald D,Nelson M,Stebbing J

更新日期：2006-11-01 00:00:00

abstract：:A lymphocele is a cystic mass that may occur in the retroperitoneum following a systematic pelvic and/or para-aortic lymphadenectomy. Lymphoceles may be the cause of severe morbidity, or rarely mortality. Symptomatic lymphoceles manifest with pain, compression of adjacent structures, lymphoedema, deep vein thrombosis ...

journal_title：Expert review of anticancer therapy

authors： Weinberger V,Cibula D,Zikan M

更新日期：2014-03-01 00:00:00

abstract：:While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trial...

journal_title：Expert review of anticancer therapy

authors： Dellinger TH,Monk BJ

更新日期：2009-07-01 00:00:00

abstract：INTRODUCTION:Cancer genome sequencing studies have discovered mutations in members of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex in nearly 25% of human cancers. The SWI/SNF complex, first discovered in S. cerevisiae, shows strong conservation from yeast to Drosophila to mammals, contains ...

journal_title：Expert review of anticancer therapy

authors： Orlando KA,Nguyen V,Raab JR,Walhart T,Weissman BE

更新日期：2019-05-01 00:00:00

abstract：:Small cell carcinoma of the urinary bladder (SCCUB) is a rare and aggressive disease. To date, no standard treatment has been proposed due to the lack of prospective studies resulting from the rarity of this disease. Recently published studies of relatively large patient cohorts, however, have shed some light on the m...

journal_title：Expert review of anticancer therapy

authors： Koga F,Yokoyama M,Fukushima H

更新日期：2013-11-01 00:00:00

abstract：INTRODUCTION:In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: tempora...

journal_title：Expert review of anticancer therapy

authors： Martínez-Pérez C,Turnbull AK,Dixon JM

更新日期：2019-02-01 00:00:00

abstract：:Bone metastases are common among patients with stage IV genitourinary cancers. Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event. These events are associated with increased medical expenses and decreased quality of life. Current guidelines recomme...

journal_title：Expert review of anticancer therapy

authors： Mulders PF,Abrahamsson PA,Bukowski RM

更新日期：2010-11-01 00:00:00

abstract：:Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combin...

journal_title：Expert review of anticancer therapy

authors： Danson SJ,Middleton MR

更新日期：2001-06-01 00:00:00

abstract：INTRODUCTION:PI3K inhibitors are an important new therapeutic option for the treatment of relapsed and refractory B-cell lymphoid malignancies. Idelalisib is a PI3Kδ inhibitor that has been approved for the treatment of lymphoma and chronic lymphocytic leukemia in the relapsed/refractory setting, and several other PI3K...

journal_title：Expert review of anticancer therapy

authors： Greenwell IB,Flowers CR,Blum KA,Cohen JB

更新日期：2017-03-01 00:00:00

abstract：:The incidence of thyroid cancer is increasing by 4% per year. Thyroid cancer has become the eighth most common malignancy diagnosed in women. Papillary cancer accounts for 80% of all thyroid cancer. The management of papillary thyroid cancer is challenging, primarily because there have been no prospective randomized t...

journal_title：Expert review of anticancer therapy

authors： Rosenbaum MA,McHenry CR

更新日期：2009-03-01 00:00:00

abstract：:Introduction: Despite dramatic improvements in survival achieved with currently available anti-HER2 agents, HER2-positive metastatic breast cancer remains an almost invariably deadly disease, with primary or acquired resistance to HER2-directed agents developing during treatment. Many efforts are focused on identifyin...

journal_title：Expert review of anticancer therapy

authors： Viale G,Morganti S,Ferraro E,Zagami P,Marra A,Curigliano G

更新日期：2019-09-01 00:00:00

abstract：:In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological pattern...

journal_title：Expert review of anticancer therapy

authors： Franceschi E,Agati R,Brandes AA

更新日期：2011-11-01 00:00:00

abstract：INTRODUCTION:Immunotherapy has emerged as a major class in the therapeutic arsenal of multiple myeloma. Cell-based immunotherapy (CAR T-cells) and monoclonal antibody-based immunotherapy (naked monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell engagers) are the two cornerstones of this novel approa...

journal_title：Expert review of anticancer therapy

authors： Jullien M,Touzeau C,Moreau P

更新日期：2020-10-26 00:00:00

abstract：:The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axil...

journal_title：Expert review of anticancer therapy

authors： Greenberg CC,Bafford AC,Golshan M

更新日期：2008-02-01 00:00:00

abstract：:The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and melanoma progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signaling can inhibit multiple cellular processes involved in melanoma progression and me...

journal_title：Expert review of anticancer therapy

authors： De Giorgi V,Grazzini M,Gandini S,Benemei S,Asbury CD,Marchionni N,Geppetti P

更新日期：2012-11-01 00:00:00

abstract：:Approximately 25% of breast cancer patients without lymph node metastases develop systemic relapse. A growing body of data supports the notion that hematogenous dissemination of breast cancer cells occurs independently of lymphatic spread of disease; however, current clinical practice does not involve routine analysis...

journal_title：Expert review of anticancer therapy

authors： Lang JE,Hall CS,Singh B,Lucci A

更新日期：2007-10-01 00:00:00

abstract：INTRODUCTION:The treatment of chronic myeloid leukemia (CML) has been drastically changed by the approval of tyrosine kinase inhibitors (TKIs). CML is now managed as a chronic disease requiring both long-term treatment and close molecular monitoring in the majority of patients. AREAS COVERED:Evidence suggests that in ...

journal_title：Expert review of anticancer therapy

authors： Stagno F,Breccia M,Di Raimondo F

更新日期：2020-12-01 00:00:00

abstract：INTRODUCTION:Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pa...

journal_title：Expert review of anticancer therapy

authors： Weinberger V,Bednarikova M,Cibula D,Zikan M

更新日期：2016-12-01 00:00:00

abstract：:Total mesorectal excision has been established as a standard surgical procedure for rectal cancer. MRI is now routinely used for preoperative staging of rectal cancer and provides accurate assessment of the tumor relative to the circumferential margin, that is, the mesorectal fascia. This identifies patients at risk o...

journal_title：Expert review of anticancer therapy

authors： Jhaveri KS,Sadaf A

更新日期：2009-04-01 00:00:00

abstract：:The failure of conventional chemotherapy to improve survival in a large percentage of patients with advanced solid tumors has prompted the development of alternative anticancer approaches. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) relies on myeloablative conditioning to eradicate the under...

journal_title：Expert review of anticancer therapy

authors： Espinoza-Delgado I,Childs RW

更新日期：2004-10-01 00:00:00

abstract：INTRODUCTION:Fertility impairment due to treatments is a major concern for adolescents and young adult patients who survived cancer. Areas covered: Chemotherapy may determine a detrimental effect on ovary function, leading to infertility, and premature ovarian failure. Embryo and oocyte cryopreservation is a standard s...

journal_title：Expert review of anticancer therapy

authors： Tosoni A,Balestrini D,Brandes AA

更新日期：2017-05-01 00:00:00